ARTICLE | Product Development
Industry to boost supply of chloroquine, hydroxychloroquine despite limited data in COVID-19
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
March 20, 2020 11:09 PM UTC
Updated on Mar 25, 2020 at 10:48 PM UTC
Novartis and Teva join a growing list of pharmas with plans to ramp up supply of antimalarial drug hydroxychloroquine in the U.S. for COVID-19 despite sparse clinical data supporting the drug's efficacy in the indication.
Chloroquine and its more tolerable derivative, hydroxychloroquine, have gained attention in light of President Donald Trump's statements during a March 19 press briefing, in which he called for widespread use of unapproved drugs under compassionate use and expressed great optimism for the antimalarials as treatment for COVID-19 (see "FDA Urged to Follow Science")...